Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


FY14 Marks Significant Commercial Milestone for Pacific Edge


FY14 Marks Significant Commercial Milestone for Pacific Edge

The 2014 Financial Year marked a significant commercial milestone for Pacific Edge as the Company celebrated the start of revenue generation in its primary market, the USA, alongside a strong year of market development and customer capture.

Pacific Edge, which develops and markets molecular diagnostic tests, primarily for the detection of bladder cancer, commercially launched its first bladder cancer product, Cxbladderc in the US market in July 2013. This diagnostic test allows urologists to evaluate patients who present to their clinic with hematuria (blood in the urine) for bladder cancer.

The USA is the world’s largest biomedical market, and has 10,500 urologists evaluating in excess of 1 million people with hematuria and investing in excess of US$1 billion in the evaluation of those patients annually. Pacific Edge has conservatively estimated that this market could provide the Company with the opportunity to develop $100 million in gross revenue at the completion of its fifth full year of trading.

Over the last 18 months, Pacific Edge has made a significant investment in the growth of the business and its entry into the American market. The Company has achieved a very rapid commercial rollout of Cxbladder in the USA, building its own laboratory, gaining regulatory approval, establishing a sales force and launching Cxbladder. All of these steps were completed on time, to specification and within budget.

For the 2014 Financial Year Ended 31 March 2014, Pacific Edge recorded a Total Comprehensive Loss after tax of $9.38 million (FY13: $6.95 million), in line with budgeted expectations. The Company reported its first substantial trading revenue and whilst still only a small number, this is a strong lift despite the short period of selling in the American market. The majority of the Net Loss is the significant investment the Company has made in the growth of the business; setting up and roll out of business in the USA, clinical trials and User Program’s with new customers, further product development and management of intellectual property1.

Chairman of Pacific Edge, Chris Swann, said: “During the year it has been affirmed to us that our product, Cxbladder, is in strong demand as an accurate tool for the detection of bladder cancer.

“Evaluating hematuria in American patients for bladder cancer is a significant market of scale and could be worth up to $100 million in gross revenue for our Company in five years’ time. It takes time to develop competency and recognition in the market and to begin establishing the relationships with our customers at a commercial level.

We have been delighted to see the first steps of our revenue generation since the appointment of sales staff in the USA in July 2013 and we are confident the momentum of the extensive commercialisation program, to familiarise the urology clinicians in the US health system with the significant benefits of Cxbladder, will accelerate sales in FY15.”

“Whilst the New Zealand and Australian markets are important to us from a product development and commercialisation process perspective, it is the scale and accessibility of the American market that is paramount to the success of the Company.”


© Scoop Media

Business Headlines | Sci-Tech Headlines


DIY: Kiwi Ingenuity And Masking Tape Saves Chick

Kiwi ingenuity and masking tape has saved a Kiwi chick after its egg was badly damaged endangering the chick's life. The egg was delivered to Kiwi Encounter at Rainbow Springs in Rotorua 14 days ago by a DOC worker with a large hole in its shell and against all odds has just successfully hatched. More>>


Trade: Key To Lead Mission To India; ASEAN FTA Review Announced

Prime Minister John Key will lead a trade delegation to India next week, saying the pursuit of a free trade agreement with the protectionist giant is "the primary reason we're going" but playing down the likelihood of early progress. More>>



MYOB: Digital Signatures Go Live

From today, Inland Revenue will begin accepting “digital signatures”, saving businesses and their accountants a huge amount of administration time and further reducing the need for pen and paper in the workplace. More>>

Oil Searches: Norway's Statoil Quits Reinga Basin

Statoil, the Norwegian state-owned oil company, has given up oil and gas exploration in Northland's Reinga Basin, saying the probably of a find was 'too low'. More>>


Modern Living: Auckland Development Blowouts Reminiscent Of Run Up To GFC

The collapse of property developments in Auckland is "almost groundhog day" to the run-up of the global financial crisis in 2007/2008 as banks refuse to fund projects due to blowouts in construction and labour costs, says John Kensington, the author of KPMG's Financial Institutions Performance Survey. More>>


Health: New Zealand's First ‘No Sugary Drinks’ Logo Unveiled

New Zealand’s first “no sugary drinks logo” has been unveiled at an event in Wellington... It will empower communities around New Zealand to lift their health and wellbeing and send a clear message about the damage caused by too much sugar in our diets. More>>


Get More From Scoop

Search Scoop  
Powered by Vodafone
NZ independent news